GlobeNewswire
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
📈
AI Sentiment
Highly Positive
8/10
- Home
- RNXT
RNXT
RenovoRx Inc.
as of 12-17-2025 1:10pm EST
$0.88
+$0.04
+4.62%
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Chart Type:
Time Range:
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 36.4M | IPO Year: | 2021 |
| Target Price: | $7.75 | AVG Volume (30 days): | 214.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $1.69 | Next Earning Date: | 11-13-2025 |
| Revenue: | $928,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2795.35% | Revenue Growth (next year): | 272.69% |
Stock Insider Trading Activity of RenovoRx Inc. (RNXT)
Agah Ramtin
Buy
Chief Medical Officer
RNXT Dec 16, 2025
Avg Cost/Share
$0.85
Shares
12,000
Total Value
$10,200.00
Owned After
778,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Dec 5, 2025
Avg Cost/Share
$0.96
Shares
10,000
Total Value
$9,600.00
Owned After
778,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Nov 24, 2025
Avg Cost/Share
$0.80
Shares
12,000
Total Value
$9,600.00
Owned After
778,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Nov 21, 2025
Avg Cost/Share
$0.80
Shares
10,000
Total Value
$8,000.00
Owned After
778,460
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Agah Ramtin | RNXT | Chief Medical Officer | Dec 16, 2025 | Buy | $0.85 | 12,000 | $10,200.00 | 778,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Dec 5, 2025 | Buy | $0.96 | 10,000 | $9,600.00 | 778,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Nov 24, 2025 | Buy | $0.80 | 12,000 | $9,600.00 | 778,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Nov 21, 2025 | Buy | $0.80 | 10,000 | $8,000.00 | 778,460 |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Compare RNXT vs Leading Stocks
See how RNXT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.